Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68
Definium Therapeutics Inc DFTX
$43.52
▼ -2.18%
($-0.97)
🎢 High Beta
Open
$44.98
Prev Close
$44.49
Day Range
$42.84 – $45.00
52W Range
$7.96 – $49.20
Market Cap
$5.78B
Beta
2.30
EPS (TTM)
$-2.49
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-05-04 |
| Shares Out. | 124,630,000 |
| Website | definiumtx.com/ ↗ |
| Phone | 12122206633 |
| Employees | 106 |
| Net Income | -$77.1M |
| Total Assets | $401.3M |
| Total Liabilities | $122.4M |
| Equity | $278.8M |
About Definium Therapeutics Inc
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Definium Therapeutics Inc is a publicly traded company under the ticker symbol DFTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)